State AGs Are Doing Work on Drug Pricing
Erin Fuse Brown writes about a new article highlighting the role of state attorneys general on improving drug price affordability.
Read MoreDrug Policy
Let’s Make a Deal…on Drug Prices
Democrats are on the brink of passing a historic set of drug price reforms. How will they impact patients, insurers and the drug industry?
Read More
Can Democrats Reconcile Their Health Policy Differences?
Democratic lawmakers face tough health care compromises as they struggle to secure votes for their blockbuster spending bill.
Read More
The Aducanumab Aftermath: The Industry
How is the pharmaceutical industry reacting to the FDA’s surprising approval of a controversial Alzheimer’s drug?
Read More
The Aducanumab Aftermath: The Payer
A costly new Alzheimer’s drug could wreak financial havoc on insurers, seniors and taxpayers.
Read More
The Aducanumab Aftermath
The Aducanumab Aftermath A SPECIAL CONVERSATION SERIES June 22, 2021 Art by Leslie Walker About this Special Series The U.S. Food and Drug Administration (FDA) recently approved the costly new Alzheimer’s drug aducanumab (now known by the brand name Aduhelm) despite doubts about its safety and efficacy. Priced at $56,000 by drugmaker Biogen, aducanumab could…
Read More
The Aducanumab Aftermath: The Doctor
One doctor grapples with questions about a controversial new Alzheimer’s drug’s safety and efficacy.
Read More
Preventing HIV Just Got A Lot Cheaper. What Took So Long?
After nearly a decade of sky-high prices, new generics have sent the price of the HIV prevention drug PrEP plummeting.
Read More